What the FDA labels say about taking them together
Cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide and zolpidem
Cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide's FDA label of February 3, 2025 names zolpidem in its drug interactions section; the zolpidem labels PlainMeds reads (4) do not name cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide. The cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide label: “Dosage reduction for midazolam should be considered, especially if more than a single dose of midazolam is administered. buspirone zolpidem With other sedative/hypnotics, dose reduction may be necessary and clinical …”
Check it at the source: the cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide FDA label on DailyMed (effective February 3, 2025, Gilead Sciences, Inc.); the zolpidem FDA label on DailyMed (effective August 15, 2022, Viatris Specialty LLC).
What does the cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide label say about zolpidem?
Cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide label, drug interactionsDosage reduction for midazolam should be considered, especially if more than a single dose of midazolam is administered. buspirone zolpidem With other sedative/hypnotics, dose reduction may be necessary and clinical monitoring is recommended.
Source: FDA drug label (Genvoya), Gilead Sciences, Inc., effective February 3, 2025 (SPL set 34784acf-15ed-4715-b504-eb30430518e9), via openFDA; the full label on DailyMed
What does the zolpidem label say about cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide?
Zolpidem's label (effective August 15, 2022) and its 3 other brand-application labels do not name cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Edluar), Viatris Specialty LLC, effective August 15, 2022 (SPL set a32884d0-85b5-11de-8a39-0800200c9a66), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide | Zolpidem | |
|---|---|---|
| Labeled for | HIV | Insomnia |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $143.35 per tablet Genvoya tablet | $0.0344 per tablet 5 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once